Yesterday, Feb. 29, 2016, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $499.80 to $7,375,492.00.

Highlighted Stocks Traded by Insiders:

Ideal Power (IPWR) - FREE Research Report

Alexander Bill, who is Chief Technology Officer at Ideal Power, sold 15,000 shares at $4.31 on Feb. 29, 2016. Following this transaction, the Chief Technology Officer owned 404,996 shares meaning that the stake was reduced by 3.57% with the 15,000-share transaction.

The shares most recently traded at $4.78, up $0.47, or 9.83% since the insider transaction. Historical insider transactions for Ideal Power go as follows:

  • 4-Week # shares bought: 258,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 258,000
  • 12-Week # shares sold: 28,000
  • 24-Week # shares bought: 258,000
  • 24-Week # shares sold: 64,063

The average volume for Ideal Power has been 16,000 shares per day over the past 30 days. Ideal Power has a market cap of $46.6 million and is part of the industrial goods sector and industrial industry. Shares are down 37.5% year-to-date as of the close of trading on Monday.

Ideal Power Inc. develops power conversion solutions with a focus on commercial and industrial grid storage, combined solar and storage, and microgrid applications. The company's principal products include power conversion systems, such as dual-port and multi-port battery converters. Currently, there are 5 analysts who rate Ideal Power a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPWR - FREE

TheStreet Quant Ratings rates Ideal Power as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Ideal Power Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gladstone Capital (GLAD) - FREE Research Report

Gladstone David, who is Ceo at Gladstone Capital, bought 3,925 shares at $6.37 on Feb. 29, 2016. Following this transaction, the Ceo owned 1.2 million shares meaning that the stake was boosted by 0.34% with the 3,925-share transaction.

The shares most recently traded at $6.88, up $0.51, or 7.41% since the insider transaction. Historical insider transactions for Gladstone Capital go as follows:

  • 4-Week # shares bought: 13,700
  • 4-Week # shares sold: 9,673
  • 12-Week # shares bought: 23,700
  • 12-Week # shares sold: 9,673
  • 24-Week # shares bought: 103,700
  • 24-Week # shares sold: 9,673

The average volume for Gladstone Capital has been 219,400 shares per day over the past 30 days. Gladstone Capital has a market cap of $153.5 million and is part of the financial sector and financial services industry. Shares are down 6.7% year-to-date as of the close of trading on Monday.

Gladstone Capital Corporation is a business development company specializing in investments in debt and equity securities. The stock currently has a dividend yield of 12.82%. The company has a P/E ratio of 12.4. Currently, there are no analysts who rate Gladstone Capital a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GLAD - FREE

TheStreet Quant Ratings rates Gladstone Capital as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Gladstone Capital Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ResMed (RMD) - FREE Research Report

Sandercock Brett, who is Chief Financial Officer at ResMed, sold 30,000 shares at $57.61 on Feb. 29, 2016. Following this transaction, the Chief Financial Officer owned 119,327 shares meaning that the stake was reduced by 20.09% with the 30,000-share transaction.

The shares most recently traded at $57.41, down $0.20, or 0.35% since the insider transaction. Historical insider transactions for ResMed go as follows:

  • 4-Week # shares sold: 4,500
  • 12-Week # shares sold: 4,500
  • 24-Week # shares sold: 34,397

The average volume for ResMed has been 1.3 million shares per day over the past 30 days. ResMed has a market cap of $8.1 billion and is part of the health care sector and health services industry. Shares are up 6% year-to-date as of the close of trading on Monday.

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The stock currently has a dividend yield of 2.08%. The company has a P/E ratio of 23.3. Currently, there are 4 analysts who rate ResMed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RMD - FREE

TheStreet Quant Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full ResMed Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.